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ABSTRACT  
Without any doubt the young technology of additive manufacturing, including 2D and 3D printing, has been 
changing the world. A wide spectrum of objects in medical and pharmaceutical field can already be successfully 
printed. This ranges from a detailed figure in the micrometer regime to a full size residential house unit made from 
concrete [Sakin et al., 2017; Doherty et al., 2020]. In the pharmaceutical sector, additive manufacturing offers the 
option of medication customization [Pravin et al., 2018]. Integrating this new technology has several advantages 
over the current, well-established but outdated “one-size-fits-all” approach. Besides avoiding medication errors, 
printing tailored oral dosage forms is financially attractive for small scale on-demand production [Awad et al., 
2018]. The development of dosage forms, production of sample batches and modification of samples can be done 
with little effort compared to generic powder-pressed pills which require heavy pharmaceutical machinery [Awad 
et al., 2018; Dachtler et al., 2020]. To further progress and to create the legal framework for the approval of 
additively manufactured drugs it requires a paradigm change of stakeholders who have the power to make 
decisions and changes [Horst et al., 2019]. 
Keywords: Healthcare Digitalization, Pharmaceutical Industry, Additive Manufacturing, 2D/3D Printing. 
 
BENEFITS OF PERSONALIZED 
MEDICATION 
Currently, the majority of pharmaceutical 
formulations have a predetermined dosage of one or 
more active ingredients [Rahman et al., 2018]. This 
is not tailored to the physiological constitution of the 
patient. Dosing drugs optimally depends on genetic, 
metabolic and gender-specific properties. Highly 
potent drugs in particular have a narrow therapeutic 
window, which varies from patient to patient. This 
calls for an individual treatment through 
personalized healthcare. Generic drugs do not meet 
the requirements for treating patients immaculately 
and there is a possibility of non-optimal or incorrect 
dosing [Reiner et al., 2020]. A wide variety of 
dosage forms and combinations of active 
pharmaceutical ingredients with tailored release 
kinetics need to be administered. This way, optimal 
therapy success is guaranteed and the risk of perilous 
medication errors is minimized. The problem of 
wrong medication should not be underestimated, as 
it is the third leading cause of death in the USA after 
cardiovascular diseases and cancer [Makary et al., 
2016]. 
The decentralized production of drugs avoids 
complex process steps involved in the “classic” 
production of solid dosage forms. The idea includes 
patient data being transmitted in digital form, for 
example from the attending physician, directly to the 
2D/3D printer in a pharmacy. The diagnosis is linked 
directly to individual medication. Small batches are 
produced cost-efficiently as required, which 
prevents drug bottlenecks or waste of active 
ingredients [Fasila et al., 2008]. Stocks of rare drugs 
can be preserved this way. 
Classic powder-pressed tablets are still the first 
choice for the mass market, as they can be produced 
time- and cost-efficiently in large quantities. 
However, individual therapy is not possible this way. 
Conventional solid dosage forms are complex 
systems made up of a wide variety of active 
ingredients and excipients [Qiu et al., 2016]. The 
development of a conventional formulation is 
therefore associated with a high level of effort due to 
possible cross-side effects.  
For new drug development, a large number of animal 
and clinical studies are necessary before a suitable 
carrier system, a generic combination of active 
ingredients and a suitable release profile can be 
found. This is where pharmaceutical 2D/3D printing 
has a decisive economic advantage. Dosage forms 
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would be developed, produced and modified at a 
minimum of cost and time.  
INDIVIDUALIZED CARE – A DISRUPTIVE 
SYSTEM 
In order to digitize the healthcare system as a whole, 
several separate players and stakeholders must be 
successfully linked. As part of a large multi-part 
disruptive system, the digital medication printing 
makes a decisive contribution to the personalization 
of medicine. Further important segments of the 
system as a whole include the use of artificial 
intelligence for data analysis, innovative methods for 
creating diagnoses and monitoring the success of 
therapy using smart data [Nohl-Deryk et al., 2018]. 
In a digitized healthcare system, active 
pharmaceutical ingredient systems are provided by 
supply companies for pharmacies, which 
manufacture tailored dosage forms on demand in 
small scales. While the doctor uses digitally obtained 
data to make an algorithm-based precision diagnosis 
for the patient, the data is forwarded directly to the 
formulator device in a pharmacy (see Figure 1). The 
reimbursement and big data collection for future 
optimization of diagnoses is carried out by the health 
insurance company [Baierlein, 2017]. Big data 
describes data sets that are, among other things, too 
large, complex, dynamic or loosely structured to be 
evaluated using conventional data processing 
methods and require innovative solutions therefore. 
 
THE FUTURE OF HEALTH CARE 
Medicine is a vivid science that lives from the 
introduction of innovations and new approaches and 
is therefore constantly developing. In the past, data 
acquisition in medicine was symptom-based and 
physicians depended their treatment on intuition. 
Today’s diagnoses are made on the basis of patterns 
which results in actions based on evidence. Future 
application of rules, algorithms and big reference 
databases not only enable actionable clinical 
decision support but also individually efficient care 
[Wilckens, 2014]. Algorithms are going to convert 
personally generated data sets to precision treatment. 
Various studies indicate that integrating technology 
and digitalization have a positive impact on 
treatment success [Frias, 2017]. Wearable sensors 
and mobile gadgets already have been shown to 
increase therapeutic adherence in some cases. 
Nevertheless, there is still a long way to complete 














Figure 1: The future of digital healthcare as a disruptive system including multiple steps to obtain optimal 
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